Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide

被引：2
|
作者：
Tiong, Ing S. [1 ,2 ,3 ]
Stevenson, William S. [4 ,5 ]
Wall, Meaghan [3 ,6 ]
Yap, Yan Zhuang [1 ]
Seymour, John F. [1 ,7 ,8 ]
Kenealy, Melita [3 ,9 ]
Blombery, Piers [1 ,7 ,8 ]
机构：
[1] Peter MacCallum Canc Ctr, 300 Grattan St, Melbourne, Vic 3000, Australia
[2] Alfred Hosp, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
[4] Royal North Shore Hosp, St Leonards, NSW, Australia
[5] Univ Sydney, Northern Clin Sch, Sydney, NSW, Australia
[6] Murdoch Childrens Res Inst, Victorian Clin Genet Serv, Melbourne, Vic, Australia
[7] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[8] Royal Melbourne Hosp, Melbourne, Vic, Australia
[9] Cabrini Hlth, Melbourne, Vic, Australia
来源：
EJHAEM | 2023年 / 4卷 / 04期
关键词：
RISK; DDX41;
D O I：
10.1002/jha2.767
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1212 / 1215
页数：4
相关论文
共 50 条
  • [1] Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)
    Tiong, Ing S.
    Stevenson, William S.
    Wall, Meaghan
    Yap, Yan Zhuang
    Seymour, John F.
    Kenealy, Melita
    Blombery, Piers
    BLOOD, 2022, 140 : 4090 - 4091
  • [2] Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
    Al-Kali, Aref
    Nanaa, Ahmad
    Viswanatha, David
    He, Rong
    Nguyen, Phuong
    Jevremovic, Dragan
    Foran, James M.
    Yi, Cecelia Arana
    Greipp, Patricia T.
    Gangat, Naseema
    Patnaik, Mrinal
    Tefferi, Ayalew
    Litzow, Mark R.
    Mangaonkar, Abhishek A.
    Shah, Mithun Vinod
    Badar, Talha
    Alkhateeb, Hassan B.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [3] Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
    Aref Al-Kali
    Ahmad Nanaa
    David Viswanatha
    Rong He
    Phuong Nguyen
    Dragan Jevremovic
    James M. Foran
    Cecelia Arana Yi
    Patricia T. Greipp
    Naseema Gangat
    Mrinal Patnaik
    Ayalew Tefferi
    Mark R. Litzow
    Abhishek A. Mangaonkar
    Mithun Vinod Shah
    Talha Badar
    Hassan B. Alkhateeb
    Blood Cancer Journal, 13
  • [4] Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
    Prebet, Thomas
    Charbonnier, Aude
    Gelsi-Boyer, Veronique
    Mozziconacci, Marie Joelle
    Blaise, Didier
    Vey, Norbert
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1538 - 1540
  • [5] Clinical experience with Azacitidine in myelodysplastic syndrome and low blast count acute myeloid leukemia
    Gawliczek, A.
    Stein, W.
    Kokowski, K.
    Kiehl, M. G.
    ONKOLOGIE, 2011, 34 : 147 - 147
  • [6] Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
    Kenealy, Melita
    Hertzberg, Mark
    Benson, Warwick
    Taylor, Kerry
    Cunningham, Ilona
    Stevenson, Will
    Hiwase, Devendra
    Eek, Richard
    Zantomio, Daniela
    Jong, Steve
    Wall, Meaghan
    Blombery, Piers
    Gerber, Tracey
    Debrincat, Marlyse
    Zannino, Diana
    Seymour, John F.
    HAEMATOLOGICA, 2019, 104 (04) : 700 - 709
  • [7] Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
    Baranwal, Anmol
    Nanaa, Ahmad
    Viswanatha, David
    He, Rong
    Foran, James
    Badar, Talha
    Hogan, William J.
    Litzow, Mark R.
    Shah, Mithun Vinod
    Patnaik, Mrinal M.
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    BONE MARROW TRANSPLANTATION, 2022, 57 (11) : 1716 - 1718
  • [8] Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
    Anmol Baranwal
    Ahmad Nanaa
    David Viswanatha
    Rong He
    James Foran
    Talha Badar
    William J. Hogan
    Mark R. Litzow
    Mithun Vinod Shah
    Mrinal M. Patnaik
    Aref Al-Kali
    Hassan B. Alkhateeb
    Bone Marrow Transplantation, 2022, 57 : 1716 - 1718
  • [9] Characteristics and Outcomes of Patients with DDX41-Mutated Acute Myeloid Leukemia: A Single-Center Experience
    Jain, Jayanshu
    Byrd, Kenneth P.
    Male, Heather J.
    Abdelhakim, Haitham
    Gonzalez-Lugo, Jesus D.
    Lin, Tara L.
    BLOOD, 2023, 142
  • [10] Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients
    Nanaa, Ahmad
    He, Rong
    Foran, James M.
    Badar, Talha
    Gangat, Naseema
    Pardanani, Animesh
    Hogan, William J.
    Litzow, Mark R.
    Patnaik, Mrinal
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 171 - 176
12345